Jade Biosciences Q2 FY26 net loss widens to $55.8 million
JBIO•Q2 loss widens as R&D and G&A rise
Jade Biosciences posted a Q2 net loss of $55.8 million, widening from $32.1 million a year earlier.
- R&D expense climbed 122.1% year over year to $50.1 million.
- G&A rose 71.2% to $8.9 million.
- Cash, cash equivalents, and investments totaled $461.2 million at June 30, with runway expected into Q4 2028.
Pipeline updates for JADE101 and JADE301
JADE101 interim Phase 1 data showed about 70% mean IgA reductions after a single 700 mg dose; Phase 2 interim data is expected in 2027.
Phase 3 for JADE101 is expected to start in H1 2027. JADE301 Phase 1 is slated for Q4 2026, with interim data in H2 2027.
